Biopharmaceutical Manufacturing, Upstream, Downstream …
Biopharmaceutical Manufacturing, Upstream, Downstream processing news. News and analysis on the clinical development and manufacture of large molecule drugs. Aditum Bio and Leads Biolabs join forces in new company to fight autoimmune diseases. The two companies have formed Oblenio Bio to develop a tri-specific T-cell engager.
‘Biotech remains the biopharma industry’s engine of innovation …
Jun 28, 2022 · Biotech performed ‘exceptionally well’ in 2021, driven by the COVID-19 crisis. That’s against a backdrop where the pandemic is projected to result in a cumulative reduction in global medicine spending of $175bn over the next seven years compared with the pre-pandemic outlook. “The vaccines and antivirals biotech has innovated to address ...
All news - biopharma-reporter.com
EMA accepts Alvotech and Advanz Pharma’s Marketing Authorization Application for biosimilar of J&J’s Simponi. AbbVie acquires Aliada Therapeutics in $1.4 billion deal. Abzena announces major expansion of its biologics manufacturing facility. Aldevron’s …
Building resilience into biotech supply chains
Jul 8, 2022 · Biotech supply chains face an uncertain future in 2022 and beyond: up against myriad challenges ranging from future pandemic outbreaks to geopolitical tensions – and, indeed, unforeseen threats. Communication and collaboration between policymakers and biotechs will be key to creating successful supply chain models, says a report from EY.
Building a biotech hub: Switzerland focuses on mRNA, CGT and …
Sep 8, 2021 · There are 314 biotech companies in Switzerland: broken down into 251 developers and 63 suppliers. Swiss life science exports were valued at CHF 99.1bn ($108bn USD) in 2020 and accounted for 44% of total exports. The sector has grown by a factor of 4.5 since 2000, when life sciences accounted for 17% of total exports, making it the strongest ...
Trends in biosimilars: Regulatory approvals in 2024
Jul 24, 2024 · The global biosimilar market is estimated to reach a size of $43.8 billion by the end of 2024, and to grow over $100 billion in the next 10 years. Biologics are expensive medications, which is driving up the popularity of biosimilars as a more cost-effective alternative. Since the first biosimilar was approved by the FDA in 2015, the amount of ...
Speed, flexibility and innovation: Rethinking the way the …
Nov 29, 2021 · CRB’s newly released biopharma market outlook: Horizons: Life Sciences , is fueled by survey insights from more than 500 pharma representatives on key issues facing their organizations. “The report is looking at all the different disruptions within the life science industry over the past 12 months, with an emphasis on mRNA and warp speed delivery, as well as other emerging trends,” said ...
Pharma and biopharma outsourcing strategies need to use an …
Oct 26, 2022 · But a new CPhI report on 'The Future of Outsourcing' advises against this approach. “Traditionally, outsourcing strategies were designed to help secure next stage funding, but many biotechs and small pharma companies are now entering development with more robust cash flows and the ability to plan further downstream," notes the report.
Biosimilar producer looking to get first to market advantage in …
Jun 23, 2021 · Bio-Thera is expected to file for regulatory approvals in China and the EU by Q1 2024, says the data provider. The Chinese company has not yet disclosed any plans related to the US trials. However, the company intends to file for regulatory approval with the US FDA, according to GlobalData’s report. Although Bio-Thera can attain first to ...
GSK, Sanofi, and Takeda align with research communities to …
Dec 6, 2022 · The pharma giants will partner with research communities from the agency for science, technology and research (A*STAR); National University of Singapore (NUS); Nanyang Technological University, Singapore (NTU Singapore) and its innovation and enterprise company, NTUitive, alongside the Singapore Institute of Technology (SIT) to boost Singapore's biologics manufacturing capabilities.